NYSE:CRMD

Cormedix Stock Insider Trading

Healthcare > Biotechnology

Buy CRMD

*Your capital is at risk

$8.23

+0.0600 (+0.734%)

At Close: Jun 03, 2026

CorMedix Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.79. In total, the insiders bought 2.07M and sold 758.39K CRMD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-64.79
● Buy	2.07M shares
● Sell	758.39K shares
66% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jan 23, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -64.79. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 04, 2026 Buy	Common Stock A-Award	Zelnick Kaufman Beth Chief Legal Officer	Officer	36 006 Value: $282.3K
Feb 04, 2026 Buy	Common Stock A-Award	Hurlburt Elizabeth Chief Operating Officer	C-Suite Officer	36 006 Value: $282.3K
Feb 04, 2026 Buy	Common Stock A-Award	Todisco Joseph Chief Executive Officer	CEO / President	77 156 Value: $604.9K
Jan 26, 2026 Buy	Common Stock A-Award	Duncan Gregory Scott Director	Director	30 453 Value: $236.3K
Jan 26, 2026 Buy	Common Stock A-Award	Dunton Alan W Director	Director	30 453 Value: $236.3K
Jan 26, 2026 Buy	Common Stock A-Award	Lefkowitz Steven W Director	Director	30 453 Value: $236.3K
Jan 26, 2026 Buy	Common Stock A-Award	Dillione Janet Director	Director	30 453 Value: $236.3K
Jan 26, 2026 Buy	Common Stock A-Award	Kaplan Myron Director	Director	30 453 Value: $236.3K
Jan 26, 2026 Buy	Common Stock A-Award	Stewart Robert A Director	Director	30 453 Value: $236.3K
Jan 23, 2026 Buy	Common Stock A-Award	Todisco Joseph Chief Executive Officer	CEO / President	225 900 Value: $1.64M
Jan 23, 2026 Sell	Common Stock F-InKind	Hurlburt Elizabeth Chief Operating Officer	C-Suite Officer	10 778 Value: $78.4K
Jan 23, 2026 Buy	Common Stock A-Award	Zelnick Kaufman Beth Chief Legal Officer	Officer	72 820 Value: $529.4K
Jan 23, 2026 Sell	Common Stock F-InKind	Blum Susan Chief Financial Officer	C-Suite Officer	9 767 Value: $71.0K
Jan 23, 2026 Buy	Common Stock A-Award	Blum Susan Chief Financial Officer	C-Suite Officer	72 820 Value: $529.4K
Jan 23, 2026 Sell	Common Stock F-InKind	Zelnick Kaufman Beth Chief Legal Officer	Officer	8 803 Value: $64.0K
Jan 23, 2026 Buy	Common Stock A-Award	Hurlburt Elizabeth Chief Operating Officer	C-Suite Officer	93 010 Value: $676.2K
Jan 23, 2026 Sell	Common Stock F-InKind	Todisco Joseph Chief Executive Officer	CEO / President	27 306 Value: $198.5K
Jan 21, 2026 Sell	Common Stock S-Sale	Dillione Janet Director	Director	10 000 Value: $68.8K
Jan 17, 2026 Sell	Common Stock F-InKind	Todisco Joseph Chief Executive Officer	CEO / President	22 665 Value: $153.7K
Jan 16, 2026 Buy	Common Stock M-Exempt	Todisco Joseph Chief Executive Officer	CEO / President	29 585 Value: $100.0K
Jan 16, 2026 Buy	Stock Option (Right to Buy Common Stock) M-Exempt	Todisco Joseph Chief Executive Officer	CEO / President	29 585 Value: $100.0K
Jan 12, 2026 Sell	Common Stock F-InKind	Hurlburt Elizabeth Chief Operating Officer	C-Suite Officer	5 794 Value: $41.4K
Jan 12, 2026 Sell	Common Stock F-InKind	Todisco Joseph Chief Executive Officer	CEO / President	17 417 Value: $124.5K
Jan 12, 2026 Buy	Stock Option (Right to Buy Common Stock) M-Exempt	Lefkowitz Steven W Director	Director	15 000 Value: $84.5K
Jan 12, 2026 Buy	Common Stock M-Exempt	Lefkowitz Steven W Director	Director	15 000 Value: $84.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CORMEDIX INC

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical setting...

Read Full Profile Here